GLIS3 Gene Expression and Clinical Outcomes in Stomach Adenocarcinoma

GLIS3 expression was upregulated in stomach adenocarcinoma tissues with a median H-score of 112 versus 39 in controls. This dataset likely contains transcriptomic and clinical data from 133 paired patient tissues and public sources like The Cancer Genome Atlas, compiled by author Qi Xiao and last updated in May 2026. It links GLIS3 expression to adverse clinicopathological features and a hazard ratio of 1.45 for overall survival.

Use Cases

• Identify prognostic biomarkers for stomach adenocarcinoma based on GLIS3 expression levels mentioned in the description
• Investigate associations between gene expression and clinical features like nodal status and survival
• Study the epithelial-mesenchymal transition and cancer stem cell-like traits in gastric cancer
• Analyze the GLIS3-TGFBR3-Hedgehog signaling axis as described in the mechanistic studies

Strengths

• Includes clinical data from 133 paired stomach adenocarcinoma tissue samples
• Integrates data from multiple public transcriptomic datasets (TCGA, GTEx, GEO)
• Provides specific statistical associations, such as a hazard ratio of 1.45 for overall survival linked to GLIS3 expression

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small at 17.1 KB, indicating limited primary data scope

Provenance

Source

figshare, author Qi Xiao

Collection Method

Likely compiled from public transcriptomic datasets (TCGA, GTEx, GEO) and original immunohistochemistry analysis of clinical samples.

Freshness

Last updated 2026-05-21 04:19:29; freshness should be verified